Xuanzhu Biopharmaceutical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	51.77	30.09	0.03	-	-
Revenue Growth (YoY)	72.03%	103672.41%	-	-	-
Cost of Revenue	18.4	14.94	2.19	-	-
Gross Profit	33.37	15.16	-2.17	-	-
Selling, General & Admin	127.08	389.51	95.69	66.4	40.64
Research & Development	124.19	186.4	239.06	350.17	197.71
Other Operating Expenses	-	2.51	2.4	0.4	0.36
Operating Expenses	251.27	578.42	337.14	416.96	238.69
Operating Income	-217.91	-563.26	-339.31	-416.96	-238.69
Interest Expense	-0.12	-0.3	-1.17	-1.09	-0.39
Interest & Investment Income	-	-	-	31.39	8
Currency Exchange Gain (Loss)	-	-	-	-0.01	0.02
Other Non Operating Income (Expenses)	-27.47	14.77	40.03	-0.1	-0.06
EBT Excluding Unusual Items	-245.5	-548.8	-300.45	-386.77	-231.11
Gain (Loss) on Sale of Investments	-	-0.02	-0.01	0.11	2.53
Gain (Loss) on Sale of Assets	-	-7.56	-	-0.02	56.02
Asset Writedown	-	-0.05	-0.1	-92.25	-
Other Unusual Items	-	-	-	17.36	10.12
Pretax Income	-245.5	-556.42	-300.56	-461.58	-162.45
Income Tax Expense	0.01	0.01	0.01	-	-
Net Income	-245.51	-556.43	-300.56	-461.58	-162.45
Net Income to Common	-245.51	-556.43	-300.56	-461.58	-162.45
Shares Outstanding (Basic)	465	451	451	395	-
Shares Outstanding (Diluted)	465	451	451	395	-
Shares Change (YoY)	3.15%	-	14.22%	-	-
EPS (Basic)	-0.53	-1.23	-0.67	-1.17	-
EPS (Diluted)	-0.53	-1.23	-0.67	-1.17	-
Free Cash Flow	-	-127.6	-117.69	-487.42	-264.9
Free Cash Flow Per Share	-	-0.28	-0.26	-1.24	-
Gross Margin	64.45%	50.37%	-	-	-
Operating Margin	-420.89%	-1871.67%	-1170020.69%	-	-
Profit Margin	-474.21%	-1848.97%	-1036420.69%	-	-
Free Cash Flow Margin	-	-424.00%	-405831.03%	-	-
EBITDA	-190.37	-535.73	-315.26	-398.82	-223.22
D&A For EBITDA	27.53	27.53	24.04	18.14	15.47
EBIT	-217.91	-563.26	-339.31	-416.96	-238.69

Source: S&P Global Market Intelligence. Standard template. Financial Sources.